Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[The new penicillins].

J C Borderon1

  • 1Centre de pédiatrie Gatien-de-Clocheville, Tours, France.

Pediatrie
|January 1, 1988
PubMed
Summary
This summary is machine-generated.

New antibacterial beta-lactams, including combinations with beta-lactamase inhibitors, offer improved treatment for bacterial infections. However, they pose a risk for selecting resistant bacteria.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[When to vaccinate or revaccinate children with neoplasms treated by chemotherapy].

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2003
Same author

Prevention of Candida colonization prevents infection in a neonatal unit.

Biology of the neonate·2003
Same author

Diet, length of gestation, and fecal short chain fatty acids in healthy premature neonates.

JPEN. Journal of parenteral and enteral nutrition·2002
Same author

Fecal short-chain fatty acids predict digestive disorders in premature infants.

JPEN. Journal of parenteral and enteral nutrition·1998
Same author

[Cervicofacial manifestations of tularemia. Apropos of a familial case].

Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Societe d'oto-laryngologie des hopitaux de Paris·1997
Same author

[Current aspects of the fecal flora of the newborn without antibiotherapy during the first 7 days of life: Enterobacteriaceae, enterococci, staphylococci].

Pathologie-biologie·1996

Area of Science:

  • Pharmacology
  • Microbiology
  • Infectious Diseases

Context:

  • Recent advancements in antibacterial agents have introduced novel beta-lactam antibiotics.
  • Beta-lactamase inhibitors (e.g., clavulanic acid, sulbactam) are now combined with beta-lactams as a therapeutic strategy.

Purpose:

  • To review new antibacterial beta-lactams and their role in combating bacterial resistance.
  • To discuss mechanisms of bacterial resistance to beta-lactams and the implications of their use.

Summary:

  • New beta-lactam antibiotics include ureidopenicillins, amidinopenicillins, monobactams, and penems.
  • Bacterial resistance mechanisms involve impaired antibiotic penetration, beta-lactamase inactivation, and altered porin expression.
  • Combinations of beta-lactams with beta-lactamase inhibitors are effective against beta-lactamase-producing bacteria, including Pseudomonas aeruginosa.

Related Experiment Videos

Impact:

  • These novel antibiotics enhance the treatment of infections caused by beta-lactamase-producing bacteria.
  • The use of these agents necessitates careful consideration due to the potential for selecting resistant bacterial strains.
  • Understanding resistance mechanisms is crucial for optimizing the clinical application of new beta-lactam antibiotics.